Pharsight

Drugs that contain Telavancin Hydrochloride

1. Vibativ patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7351691 CUMBERLAND Glycopeptide phosphonate derivatives
May, 2021

(2 years ago)

US7208471 CUMBERLAND Glycopeptide phosphonate derivatives
May, 2021

(2 years ago)

US6635618 CUMBERLAND Glycopeptide phosphonate derivatives
Sep, 2023

(7 months ago)

US7531623 CUMBERLAND Hydrochloride salts of a glycopeptide phosphonate derivative
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101575 CUMBERLAND Glycopeptide phosphonate derivatives
May, 2021

(2 years ago)

US7700550 CUMBERLAND Glycopeptide phosphonate derivatives
May, 2021

(2 years ago)

US7544364 CUMBERLAND Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
May, 2021

(2 years ago)

US8158580 CUMBERLAND Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
May, 2021

(2 years ago)

US7008923 CUMBERLAND Glycopeptide phosphonate derivatives
May, 2021

(2 years ago)

US6872701 CUMBERLAND Glycopeptide phosphonate derivatives
Jun, 2021

(2 years ago)

US6858584 CUMBERLAND Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Aug, 2022

(1 year, 7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-673) Jun 21, 2016
New Chemical Entity Exclusivity(NCE) Sep 11, 2014

NCE-1 date: 11 September, 2013

Market Authorisation Date: 11 September, 2009

Treatment: Method of treating bacterial infections; Method of treating a staphylococcal infection; Method for treating bacterial infection

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

VIBATIV family patents

Family Patents